Patient portals do not improve hospital outcomes

Patient portals are meant to improve patient knowledge and engagement, but the current use of portals has not produced significant differences in outcomes, according to a study published in the Journal of Informatics in Health and Biomedicine.

Patient portals allow patients to take health into their own hands by offering a single platform to access medical records and interact with clinicians. However, evidence whether they improve outcomes, readmission or mortality is lacking. In this study, researchers examined if patients using portals during hospitalization experienced improved hospital outcomes, 30-day readmissions, inpatient mortality and 30-day mortality.

The study included a total of 7,538 patients who had signed up for a patient portal account before being hospitalized at Mayo Clinic Hospital in Jacksonville, Florida, from August 1, 2012, to July 31, 2014. Results showed 1,566 (20.8 percent) of patients used the portal while hospitalized. Patients who used the portal were likely to be younger, have fewer elective admissions, were more often admitted to medical services and more likely to have liver disease. Overall, researchers noted no significant difference between patients using the portal and those who did not in 30-day readmissions, inpatient mortality and 30-day mortality.

“Use of the patient portal in the inpatient setting may not improve hospital outcomes,” concluded first author Adrian Dumitrascu, with Mayo Clinic. “Future research should examine the association of portal use with more immediate inpatient health outcomes such as patient experience, patient engagement, medication reconciliation, and prevention of adverse events.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.